Safety of propiverine hydrochloride in Glaucoma

Mey, C. De; Petkova, N.; Rankova, Charita B.; Gatchev, Emil; Braeter, Manfred; Vlahov, V.

doi:10.1016/s1569-9056(03)80116-1

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11 In one study, treatment with propiverine was found to be well-tolerated and safe in patients with primary open-angle glaucoma and primary angle-closure glaucoma. 33 In a study by Madersbacher et al, it was emphasized that propiverine may be a safe treatment option except for patients with angle-closure glaucoma who have not been examined for ophthalmological safety. In addition, in the same study, they examined 6 clinical studies in which patients were given propiverine for up to 12 months and followed up to 1-2.5 years, and they emphasized that the rates of adverse events were between 8.7% and 22.7% and stated that no serious side effects were encountered.…”

Section: Overview Of Literaturementioning

confidence: 99%

Efficacy and safety of propiverine in patients with overactive bladder and neurogenic detrusor overactivity

Faikoglu¹,

Saygisever-Faikoglu²,

Ozcan³

et al. 2022

PPIJ

View full text Add to dashboard Cite

Purpose:The purpose of this review is to evaluate the efficacy and safety of propiverine in pediatric and adult patients, which is used in the symptomatic treatment of urgency urinary incontinence and urinary frequency and/or urinary incontinence in patients with neurogenic detrusor overactivity due to overactive bladder or spinal cord injuries.Method: Literature was retrieved by a PubMed search, using different combinations of pertinent keywords (e.g., propiverine, overactive bladder, neurogenic detrusor overactivity), without any limitations in terms of the publication date and language. Papers that assessed the therapeutic efficacy and tolerability of propiverine in patients with overactive bladder or neurogenic detrusor overactivity were selected for inclusion according to their relevance for the topic, as judged by the authors. Results:Propiverine is reported to be a significantly effective and safe treatment option in adult and pediatric patients with overactive bladder or neurogenic detrusor overactivity. It is observed that propiverine provides an increase in life quality without affecting cognitive functions, and may be a safe treatment option, except for patients with angleclosure glaucoma, who have not been examined in terms of ophthalmological reliability. It was observed that no changes were observed in cardiac parameters in patients receiving propiverine treatment, and there was no clinically significant difference in the incidence of side effects between the two groups in studies comparing elderly and young patients. Propiverine is recommended by the pediatric committee at the International Incontinence Consultation with the highest level of evidence (1B/C) of all anticholinergics. Conclusion:Propiverine is an effective and safe treatment option that can be the first choice in the symptomatic treatment of both adult and pediatric patients with overactive bladder or neurogenic detrusor overactivity, with its high efficacy and significantly higher tolerability.

show abstract

Section: Overview Of Literaturementioning

confidence: 99%